Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in... (Business Wire) +++ ABIONYX Aktie -4,27%

CRESCO LABS Aktie

 >CRESCO LABS Aktienkurs 
1.462 EUR    +33.3%    (Tradegate)
Ask: 1.489 EUR / 0 Stück
Bid: 1.435 EUR / 0 Stück
Tagesumsatz: 213022 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
CRESCO LABS Aktie über LYNX handeln
>CRESCO LABS Performance
1 Woche: +113,1%
1 Monat: +83,3%
3 Monate: +70,9%
6 Monate: +226,0%
1 Jahr: +61,7%
laufendes Jahr: +87,8%
>CRESCO LABS Aktie
Name:  CRESCO LABS INC. SUB. VTG
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA22587M1068 / A2PAHM
Symbol/ Ticker:  6CQ (Frankfurt)
Kürzel:  FRA:6CQ, ETR:6CQ, 6CQ:GR
Index:  -
Webseite:  https://www.crescolabs.co..
Profil:  Cresco Labs Inc. is a prominent entity within the ..
>Volltext..
Marktkapitalisierung:  288.81 Mio. EUR
Unternehmenswert:  641.06 Mio. EUR
Umsatz:  573.3 Mio. EUR
EBITDA:  122.11 Mio. EUR
Nettogewinn:  -44.59 Mio. EUR
Gewinn je Aktie:  -0.13 EUR
Schulden:  494.19 Mio. EUR
Liquide Mittel:  66.97 Mio. EUR
Operativer Cashflow:  64.29 Mio. EUR
Bargeldquote:  0.81
Umsatzwachstum:  -13.79%
Gewinnwachstum:  27.05%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  CRESCO LABS
Letzte Datenerhebung:  17.12.25
>CRESCO LABS Kennzahlen
Aktien/ Unternehmen:
Aktien: 340.49 Mio. St.
Frei handelbar: 98.33%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 2900
Umsatz/Mitarb.: 0.2 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 77.41%
Bewertung:
KGV: -
KGV lG: -
KUV: 0.39
KBV: 0.8
PEG-Ratio: -
EV/EBITDA: 5.25
Rentabilität:
Bruttomarge: 45.7%
Gewinnmarge: -7.78%
Operative Marge: 12.48%
Managementeffizenz:
Gesamtkaprendite: -4%
Eigenkaprendite: -12.02%
>CRESCO LABS Peer Group

Es sind 182 Aktien bekannt.
 
21.11.25 - 16:00
TLRY vs. CRLBF: Which Cannabis Player Offers Greater Upside? (Zacks)
 
Tilray Brands' global expansion and strong Canadian momentum spotlight its edge as investors weigh upside against Cresco Labs' slower growth....
08.11.25 - 02:30
Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
 
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -66.67% and +0.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...
05.11.25 - 12:48
Cresco Labs reports Q3 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.11.25 - 12:33
Cresco Labs Delivers Strong Q3, Maintains Market Leadership, and Unlocks New Growth Opportunities (Business Wire)
 
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the third quarter ended September 30, 2025. All financial information presented in this release is reported in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated, and is available on the Company's investor website, here. Third Quarter 2025 Highlights Third quarter revenue of $165 million. Third quarter operating cash flow of $6 million. Gross profit of $79 million. Adjusted gross profit1 of $80 million; and an Adjusted gross margin1 of 48.8%. SG&A of $52 million or 31.3% of revenue. Net loss of $22 million, includes a $16 million loss for debt extinguishment related to the refinancing of the Company's senior secured term loan, and non-cash impairment charges of $2 mi...
04.11.25 - 18:03
Cresco Labs Q3 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.10.25 - 12:36
Cresco Labs to Report Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire)
 
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or “Company”), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today announced it will report financial results for the third quarter ended September 30th, 2025 on Wednesday, November 5, 2025 before the market opens. The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights. Event: Cresco Labs Third Quarter 2025 Earnings Conference Call Date: Wednesday, November 5, 2025 Time: 8:30 am ET Webcast: LINKConference Call Registration: LINKDial-in: 1-833-470-1428 (US Toll Free), 1-646-844-6383 (US Local) Access Code: 307245 Archived access to the webcast will be available for one year on the Cresco Labs investor relations website. About Cresco Labs Inc. Cresco Labs' mission is to normalize and professionalize the cannabis industry through a CPG ap...
29.09.25 - 17:18
CSE Bulletin: MOC Eligibility Update (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - September 29, 2025) - The following CSE-Listed symbol will become MOC Eligible as detailed below. Symbol Company Name Effective Date CL Cresco Labs Inc. - Subor......
17.09.25 - 01:54
Cresco Labs Announces Voting Results of Its Annual General and Special Meeting of Shareholders (Business Wire)
 
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the results of its annual general and special meeting of shareholders (the “Meeting”) held on September 16, 2025. At the Meeting, the number of directors of the Company for the ensuing year was fixed at seven (7) and the following nominees for election as directors of the Company were elected by a majority of votes cast by the shareholders virtually present or represented by proxy at the Meeting: Charles Bachtell Gerald F. Corcoran Robert M. Sampson Thomas J. Manning Marc Lustig Michele Roberts Randy D. Podolsky  In addition, Baker Tilly US, LLP was appointed as the Company's auditor for the ensuing year. Shareholders also voted to approve the Company's Award Exchange Program (the “Award Exchange”). Under the Award Exchange, certain employees were given the option to exchange certain underwater options for a like number of full value awards with new three-year...
13.08.25 - 23:18
Cresco Labs Closes $325 Million Senior Secured Term Loan Refinancing (Business Wire)
 
Transaction Extends Maturity to 2030, Strengthens Balance Sheet and Positions Company for GrowthCHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the closing of its previously announced refinancing of the Company's senior secured credit facility. The new US$325 million senior secured term loan bears an interest rate of 12.5% per annum and matures on August 13, 2030. It replaces the Company's prior US$360 million facility, reducing total debt, extending the maturity to 2030, and providing enhanced flexibility to prepay up to US$125 million at a reduced premium. “This transaction is another milestone in our disciplined approach to capital management,” said Charlie Bachtell, CEO of Cresco Labs. “We have strengthened our balance sheet and removed near-term refinancing risk. With this foundation in place, we can remain focused on executing our growth strategy.” Proceeds from the new facility, together with cash on ...
07.08.25 - 17:30
Cresco Labs Inc. (CRLBF) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
 
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -25.00% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...
07.08.25 - 13:03
Cresco Labs reports Q2 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.08.25 - 12:33
Cresco Labs Solid Q2 Performance and Debt Refinancing Strengthen Foundation for Long-Term Value Creation (Business Wire)
 
 CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the second quarter ended June 30, 2025. All financial information presented in this release is reported in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated, and is available on the Company's investor website, here. Second Quarter 2025 Highlights Second quarter revenue of $164 million. Second quarter operating cash flow of $9 million. Gross profit of $83 million. Adjusted gross profit1 of $83 million; and an Adjusted gross margin1 of 50.6% of revenue. SG&A of $51 million or 31.4% of revenue. Net loss of $14 million, includes non-cash impairment charges of $9 million related to California assets being considered held for sale. Second quarter Adjusted EBITDA1 of $41 ...
06.08.25 - 22:36
Cresco Labs Announces Commitments to Refinance its Senior Secured Credit Facility (Business Wire)
 
Will Reduce Debt and Reinforces Commitment to Prudent Capital ManagementCHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced that it has successfully obtained commitments to refinance its senior secured credit facility (the “Senior Loan”). The refinancing, upon closing, will provide for a new senior secured term loan totaling US$325 million, bearing an interest rate of 12.5% per annum, and maturing on the 5th year anniversary of the closing of the refinancing. The new facility will replace the Company's existing US$360 million credit facility, providing enhanced financial flexibility and favorable terms, including provisions that will allow for the prepayment of up to US$125 million at a reduced prepayment premium. The refinancing comes at a time when access to capital remains highly constrained across the U.S. cannabis sector. With an estimated $2 billion in industry debt maturities coming due over the next 18 months...
17.07.25 - 12:36
Cresco Labs to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
 
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or “Company”), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today announced it will report financial results for the second quarter ended June 30th, 2025 on Thursday, August 7, 2025 before the market opens. The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights. Event: Cresco Labs Second Quarter 2025 Earnings Conference Call Date: Thursday, August 7, 2025 Time: 8:30 am ET Webcast: LINKConference Call Registration: LINKDial-in: 1-833-470-1428 (US Toll Free), 1-404-975-4839 (US Local) Access Code: 158138 Archived access to the webcast will be available for one year on the Cresco Labs investor relations website. About Cresco Labs Inc. Cresco Labs' mission is to normalize and professionalize the cannabis industry through a CPG approach to...
11.07.25 - 15:15
Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold? (Zacks)
 
CRLBF is down 24% YTD as U.S.-only exposure, falling margins and tighter regulations weigh on its cannabis business....
09.06.25 - 18:42
EXCLUSIVE: Cresco Labs CEO Says Cannabis Industry To Hold White House Accountable For Campaign Promises: €We€ll Take Any Movement At A Federal Level€ (Benzinga)
 
At the 2025 Benzinga Cannabis Capital Conference, Cresco Labs CEO Charlie Bachtell shared thoughts on what comes next for the cannabis sector. read more...
02.06.25 - 16:57
Cresco Labs targets margin expansion and disciplined growth with $162M cash balance while navigating Illinois seed-to-sale transition (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.05.25 - 01:00
Cresco Labs Inc. (CRLBF) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
 
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -33.33% and 0.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...
30.05.25 - 12:39
Cresco Labs reports Q1 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.05.25 - 12:33
Cresco Labs Continues Track Record of Delivering Strong Operating Cash Flow (Business Wire)
 
Q1 operating cashflow of $30 millionCHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the first quarter ended and year ended March 31, 2025. All financial information presented in this release is reported in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated, and is available on the Company's investor website, here. First Quarter 2025 Highlights First quarter revenue of $166 million. First quarter operating cash flow of $30 million and Free Cash Flow1 of $25 million. Gross profit of $79 million. Adjusted gross profit1 of $82 million; and an Adjusted gross margin1 of 49% of revenue. SG&A of $58 million or 35% of revenue. Net loss of $15 million. First quarter Adjusted EBITDA1 of $36 million and Adjusted EBITDA margin1...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!